Journalartikel

Jahr der Veröffentlichung: 2022

Seiten: 557-568

Zeitschrift: Trends in Pharmacological Sciences

Bandnummer: 43

Heftnummer: 7

ISSN: 0165-6147

eISSN: 1873-3735

Open Access Status: Hybrid

DOI Link: https://doi.org/10.1016/j.tips.2022.04.004

Verlag: Cell Press

Abstract: 
Despite the great success of vaccines that protect against RNA virus infections, and the development and clinical use of a limited number of RNA virus-specific drugs, there is still an urgent need for new classes of antiviral drugs against circulating or emerging RNA viruses. To date, it has proved difficult to efficiently suppress RNA virus replication by targeting host cell functions, and there are no approved drugs of this type. This opinion article discusses the recent discovery of a pronounced and sustained antiviral activity of the plant-derived natural compound thapsigargin against enveloped RNA viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza A virus. Based on its mechanisms of action, thapsigargin represents a new prototype of compounds with multimodal host-directed antiviral activity.

Harvard-Zitierstil: Shaban, M., Mayr-Buro, C., Meier-Soelch, J., Albert, B., Schmitz, M., Ziebuhr, J., et al. (2022) Thapsigargin: key to new host-directed coronavirus antivirals?, Trends in Pharmacological Sciences, 43(7), pp. 557-568. https://doi.org/10.1016/j.tips.2022.04.004

APA-Zitierstil: Shaban, M., Mayr-Buro, C., Meier-Soelch, J., Albert, B., Schmitz, M., Ziebuhr, J., & Kracht, M. (2022). Thapsigargin: key to new host-directed coronavirus antivirals?. Trends in Pharmacological Sciences. 43(7), 557-568. https://doi.org/10.1016/j.tips.2022.04.004